InflaRx posts H1 loss as warrant fair-value hit outweighs FX gains, R&D spending falls
IFRX•Costs decline as liquidity improves
R&D expense declined to EUR 8.91 million from EUR 14.22 million, driven by lower third-party spend and reduced share-based compensation.
G&A expense dropped to EUR 5.73 million from EUR 8.34 million on lower legal and consulting costs, plus lower personnel expense.
Liquidity strengthened via a $150 million share offering, lifting available funds to EUR 158.4 million; runway projected into end-2029.
H1 loss widens on warrant fair-value hit
InflaRx posted a net loss of EUR 16.24 million for the six months ended June 30, 2026, reflecting a research-focused model with no product revenue.
Revenue fell to zero from EUR 39,432 due to the December 2025 halt of active GOHIBIC sales efforts in the US.
